Literature DB >> 17447827

Use of non-benzodiazepine hypnotics in the elderly: are all agents the same?

Christian Dolder1, Michael Nelson, Jonathan McKinsey.   

Abstract

Sleep disorders, especially insomnia, are common in older adults. These disorders are frequently treated using non-benzodiazepine hypnotics. Nonetheless, there is a relative lack of data regarding the use of these agents in the elderly, and whether any of these medications is superior to any other in the class when used in the elderly is also unclear. In this article, we review, by way of the published literature, the pharmacodynamics, pharmacokinetics, drug interactions, efficacy and safety of zolpidem, zaleplon, zopiclone, eszopiclone and ramelteon in the elderly. Special emphasis is placed on identifying relevant differences between these medications when used in older adults with insomnia. Based primarily on data from placebo-controlled trials, the non-benzodiazepines reviewed were found to be most effective at improving sleep latency and sleep quality, and least effective at enhancing total sleep time. The efficacy of ramelteon was limited to improving sleep latency, while all other agents, especially at higher doses, were found to produce improvement in both sleep latency and some improvement in total sleep time. All of the medications were found to be well tolerated in the elderly. From pharmacokinetic and drug-drug interaction perspectives, zaleplon and ramelteon offer the advantage of not being primarily metabolised via the cytochrome P450 3A4 isoenzyme. In conclusion, based on relatively limited data, zopiclone, zolpidem, zaleplon, eszopiclone and ramelteon represent modestly effective and generally well tolerated treatments for insomnia in older adults. While some actual and potential differences exist among these medications, more comparative trials are needed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17447827     DOI: 10.2165/00023210-200721050-00003

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  89 in total

Review 1.  Pharmacokinetics in older persons.

Authors:  Barry J Cusack
Journal:  Am J Geriatr Pharmacother       Date:  2004-12

Review 2.  International Union of Pharmacology. XV. Subtypes of gamma-aminobutyric acidA receptors: classification on the basis of subunit structure and receptor function.

Authors:  E A Barnard; P Skolnick; R W Olsen; H Mohler; W Sieghart; G Biggio; C Braestrup; A N Bateson; S Z Langer
Journal:  Pharmacol Rev       Date:  1998-06       Impact factor: 25.468

Review 3.  Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia.

Authors:  K J Holm; K L Goa
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

4.  Medication use and risk of falls.

Authors:  C Ineke Neutel; Sheril Perry; Colleen Maxwell
Journal:  Pharmacoepidemiol Drug Saf       Date:  2002-03       Impact factor: 2.890

5.  Residual effects of middle-of-the-night administration of zaleplon and zolpidem on driving ability, memory functions, and psychomotor performance.

Authors:  Joris C Verster; Edmund R Volkerts; Antonia H C M L Schreuder; Erik J E Eijken; Janet H G van Heuckelum; Dieuwke S Veldhuijzen; Marinus N Verbaten; Isabelle Paty; Mona Darwish; Philippe Danjou; Alain Patat
Journal:  J Clin Psychopharmacol       Date:  2002-12       Impact factor: 3.153

6.  Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo.

Authors:  D J Greenblatt; J S Harmatz; L L von Moltke; B L Ehrenberg; L Harrel; K Corbett; M Counihan; J A Graf; M Darwish; P Mertzanis; P T Martin; W H Cevallos; R I Shader
Journal:  Clin Pharmacol Ther       Date:  1998-11       Impact factor: 6.875

7.  Factors influencing prescription of CNS medications in different elderly populations.

Authors:  David Craig; A Peter Passmore; Ken J Fullerton; Timothy R O Beringer; David H Gilmore; Vivienne L S Crawford; Patricia M McCaffrey; Anne Montgomery
Journal:  Pharmacoepidemiol Drug Saf       Date:  2003 Jul-Aug       Impact factor: 2.890

8.  Multicenter, double-blind, controlled comparison of zolpidem and triazolam in elderly patients with insomnia.

Authors:  M Roger; P Attali; J P Coquelin
Journal:  Clin Ther       Date:  1993 Jan-Feb       Impact factor: 3.393

9.  Effects on postural oscillation and memory functions of a single dose of zolpidem 5 mg, zopiclone 3.75 mg and lormetazepam 1 mg in elderly healthy subjects. A randomized, cross-over, double-blind study versus placebo.

Authors:  Hervé Allain; Danièle Bentué-Ferrer; Antoine Tarral; Jean-Marc Gandon
Journal:  Eur J Clin Pharmacol       Date:  2003-05-17       Impact factor: 2.953

10.  A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia.

Authors:  Martin Scharf; Milton Erman; Russell Rosenberg; David Seiden; W Vaughn McCall; David Amato; Thomas C Wessel
Journal:  Sleep       Date:  2005-06       Impact factor: 5.849

View more
  16 in total

Review 1.  Anticoagulation and psychotropic medications.

Authors:  Maurice Bachawati
Journal:  Curr Psychiatry Rep       Date:  2010-06       Impact factor: 5.285

2.  [Insomnia in the elderly. An under-diagnosed and over-treated syndrome].

Authors:  S Schwarz; L Frölich; M Deuschle
Journal:  Internist (Berl)       Date:  2010-07       Impact factor: 0.743

3.  Zolpidem and zopiclone impair similarly monotonous driving performance after a single nighttime intake in aged subjects.

Authors:  Marie-Laure Bocca; Sullivan Marie; Véronique Lelong-Boulouard; Françoise Bertran; Colette Couque; Tsellina Desfemmes; Catherine Berthelon; Jean-Noel Amato; Michèle Moessinger; Magalie Paillet-Loilier; Antoine Coquerel; Pierre Denise
Journal:  Psychopharmacology (Berl)       Date:  2010-11-18       Impact factor: 4.530

4.  Efficacy and Safety of Doxepin 1 mg and 3 mg in a 12-week Sleep Laboratory and Outpatient Trial of Elderly Subjects with Chronic Primary Insomnia.

Authors:  Andrew D Krystal; H Heith Durrence; Martin Scharf; Philip Jochelson; Roberta Rogowski; Elizabeth Ludington; Thomas Roth
Journal:  Sleep       Date:  2010-11       Impact factor: 5.849

5.  Starting insomnia treatment: the use of benzodiazepines versus z-hypnotics. A prescription database study of predictors.

Authors:  Anne M Hausken; Kari Furu; Svetlana Skurtveit; Anders Engeland; Jørgen G Bramness
Journal:  Eur J Clin Pharmacol       Date:  2008-09-23       Impact factor: 2.953

Review 6.  Melatonin prolonged release: in the treatment of insomnia in patients aged ≥55 years.

Authors:  Katherine A Lyseng-Williamson
Journal:  Drugs Aging       Date:  2012-11       Impact factor: 3.923

Review 7.  Eszopiclone: a review of its use in the treatment of insomnia.

Authors:  Philip I Hair; Paul L McCormack; Monique P Curran
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 8.  The clinical and forensic toxicology of Z-drugs.

Authors:  Naren Gunja
Journal:  J Med Toxicol       Date:  2013-06

9.  Treatment of Late-life Insomnia.

Authors:  Christina S McCrae; Joseph M Dzierzewski; Daniel Kay
Journal:  Sleep Med Clin       Date:  2009-12-01

Review 10.  Ramelteon: a review of its use in insomnia.

Authors:  Dene Simpson; Monique P Curran
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.